Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant

University of British Columbia

$1,232,800.00

A high-throughput single-cell technology for the function-based discovery of monoclonal antibody antagonists of G-protein coupled receptors in cancer

FY 2013-14

Summary
Antibodies are proteins that are naturally made by the body to fight infections and disease. The immune system is capable of making an immense diversity of different antibodies, each able to recognize and eliminate a specific target (e.g. a virus, bacteria, protein, cancer cell...). Like a lock and key, antibodies have the unique ability to specifically recognize and bind one, and only one, target. In addition to their central role in immunity, this amazing specificity also makes antibodies an extremely effective class of drugs that can be used for targeted therapies with improved effectiveness and minimal side effects. For this reason, antibody-based drugs are currently the fastest growing class of therapeutic and are being used in the treatment of many diseases including cancer, autoimmune disorders, inflammation, and infection. However, finding antibodies with desired therapeutic properties remains one of the most serious obstacles to advancing new therapies. In this project, we will develop a new technology that dramatically increases the speed and efficiency of finding antibodies that are suitable for drug development. We will apply this technology to discover new antibodies that block biological signals that drive growth and metastasis in cancer.
Program
Operating Grant
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
307343
Name
Hansen Carl L
Region
British Columbia
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Genomics: Systems and computational biology
Projecttitle
A high-throughput single-cell technology for the function-based discovery of monoclonal antibody antagonists of G-protein coupled receptors in cancer
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$1,232,800
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Antibody Selection; Antibody Therapeutics; G-Protein Coupled Receptors; Immunogenomics; Microfluidics; Receptor Antagonists; Single Cell Analysis
Abstract
Antibodies are proteins that are naturally made by the body to fight infections and disease. The immune system is capable of making an immense diversity of different antibodies, each able to recognize and eliminate a specific target (e.g. a virus, bacteria, protein, cancer cell...). Like a lock and key, antibodies have the unique ability to specifically recognize and bind one, and only one, target. In addition to their central role in immunity, this amazing specificity also makes antibodies an extremely effective class of drugs that can be used for targeted therapies with improved effectiveness and minimal side effects. For this reason, antibody-based drugs are currently the fastest growing class of therapeutic and are being used in the treatment of many diseases including cancer, autoimmune disorders, inflammation, and infection. However, finding antibodies with desired therapeutic properties remains one of the most serious obstacles to advancing new therapies. In this project, we will develop a new technology that dramatically increases the speed and efficiency of finding antibodies that are suitable for drug development. We will apply this technology to discover new antibodies that block biological signals that drive growth and metastasis in cancer.
Competitiondate
201403
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Hansen, Carl L
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $1,232,800~ $0~